Current Best Evidence in Pigmentary Dermatology
May 2024
in “
Pigment International
”
New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide → 
Studysummary In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviews treatments for pigmentary disorders, highlighting several studies. A phase 2b trial with 364 patients found oral ritlecitinib effective for nonsegmental vitiligo over 48 weeks. A study with 19 participants showed micro-needling with 5-FU was more effective than tacrolimus for vitiligo. Preliminary research suggested a role of varicella-zoster virus in segmental vitiligo. A trial with 40 melasma patients found 30% metformin cream as effective as triple combination cream. Another study with 20 vitiligo patients indicated that fractional CO2 laser, PRP, and NB-UVB significantly reduced vitiligo patch size. Further research is recommended to confirm these findings.
